Peptide inhibition occurs rapidly with no effect on cell viability. (A) Caerin 1.1 (20 μM), caerin 1.9 (5 μM), caerin 4.1 (20 μM), or PBS was incubated with 3 × 104 IFU of HIV-R5. At the times shown, virus-peptide solutions were diluted to a concentration that resulted in minimal activity based the results shown in Fig. 1B (fourfold) in complete RPMI medium with 3 × 104 T cells and incubated at 37°C for 3 days. Cells were harvested, fixed, and analyzed for GFP expression by flow cytometry. Data were normalized to infection following PBS treatment and are presented as the mean of three replicate samples from one representative experiment of three independent experiments, with error bars indicating standard deviation. (B) Peptides were incubated for 5 min at increasing concentrations (1 to 48 μM) with 5 × 104 activated primary CD4+ T cells (circles) or Hut/CCR5 cells (squares) infected with HIV-R5 at an MOI of 1, diluted fourfold with complete RPMI medium, and incubated at 37°C for 3 days. Cells were harvested and analyzed for GFP expression (closed circles and squares). Data are normalized to infection following PBS treatment and are presented as the mean of three replicate samples from one representative experiment of three independent experiments with error bars indicating standard deviation. At 2 h postinfection, 2 × 104 T cells were removed from the culture, stained with PI, and analyzed for viability by flow cytometry (open circles and squares). (C) Peptides were incubated for 5 min at increasing concentrations (1 to 50 μM) with 5 × 104 CFSE-labeled primary CD4+ T cells. Cells were then diluted fourfold with complete RPMI medium and activated by T-cell receptor engagement as previously described (41). The activated cells were cultured for 4 days, and CFSE fluorescence intensity was measured by flow cytometry. Representative histograms (panel B, insets) from each peptide treatment are shown (40 μM caerin 1.1, 10 μM caerin 1.9, and 40 μM caerin 4.1), which were identical to those of the cells not treated with peptides.